Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)

Trial Profile

Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Axitinib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ADONIS
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top